No annual revenue total was found in Rezolute, Inc.'s SEC filings.
Rezolute, Inc. (RZLT) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $107.8 million in cash and investments and $934,000 in total debt.
Revenue
—
Net income
$-77.59M
-4.3% vs prior year
Operating cash flow
$-64.64M
+6.4% vs prior year
Free cash flow
$-44.63M
-84.7% vs prior year
EPS
$-0.75
+23.5% vs prior year
Dividend per share
None
Shares outstanding
96.72M
+6.5% vs prior year
Net cash
$106.87M
FY 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RZLT (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Redwood City, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1509261
- Former names
- AntriaBio, Inc. (until Dec 7, 2017); FITS MY STYLE INC (until Jan 11, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Jun 30, 2026 |
FY 2025 Jun 30, 2025 |
FY 2024 Jun 30, 2024 |
FY 2023 Jun 30, 2023 |
FY 2022 Jun 30, 2022 |
|---|---|---|---|---|---|
| Operating income | -$83.0M | -$79.9M | -$70.4M | -$56.0M | -$41.8M |
| Net income | -$77.6M | -$74.4M | -$68.5M | -$51.8M | -$41.1M |
| Diluted EPS | -$0.75 | -$0.98 | -$1.33 | -$1.01 | -$2.32 |
| Operating cash flow | -$64.6M | -$69.1M | -$57.4M | -$44.5M | -$39.6M |
| Free cash flow | — | — | — | -$44.6M | — |
| Total assets | $112.8M | $175.5M | $132.7M | $123.7M | $152.4M |
| Total liabilities | $12.2M | $13.4M | $11.7M | $7.5M | $2.9M |
| Stockholders' equity | $100.7M | $162.1M | $121.0M | $116.2M | $149.5M |
| Cash and investments | $107.8M | $167.9M | $127.1M | $118.4M | $150.4M |
| Total debt | $934,000 | $1.6M | $2.2M | $2.5M | $188,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 14, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 5, 2026 | Oct 5, 2026 |
| 10-K | Annual report | Sep 24, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Sep 24, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 2, 2026 | Jun 2, 2026 |
All 755 Rezolute, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.